Methoxsalen solution - Therakos
Alternative Names: Methoxsalen sterile solution - Therakos; UVADEXLatest Information Update: 13 Mar 2025
At a glance
- Originator Therakos
- Developer Mallinckrodt Inc.; Therakos
- Class Antineoplastics; Antipsoriatics; Coumarins; Psoralens; Small molecules
- Mechanism of Action DNA cross linking agents; Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cutaneous T-cell lymphoma
- Registered Graft-versus-host disease
Most Recent Events
- 28 Feb 2025 Therakos suspends a phase II trial in Colitis in USA prior to the enrolment due to the re-evaluation of the study design and strategy for expansion of trial by the sponsor(NCT06646016)
- 17 Oct 2024 Therakos plans a phase II trial for Colitis (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) (Extracorporeal, Liquid), in January 2025 (NCT06646016) (MNK60052002)
- 30 Dec 2022 Mallinckrodt Pharmaceuticals has patent protection for Methoxsalen solution in USA and other countries